Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma.
Advanced hepatocellular carcinoma
Lenvatinib
Vascular endothelial growth factor
Journal
Case reports in gastroenterology
ISSN: 1662-0631
Titre abrégé: Case Rep Gastroenterol
Pays: Switzerland
ID NLM: 101474819
Informations de publication
Date de publication:
Historique:
received:
03
12
2019
accepted:
06
01
2020
entrez:
29
2
2020
pubmed:
29
2
2020
medline:
29
2
2020
Statut:
epublish
Résumé
Lenvatinib is a first-line standard treatment for advanced hepatocellular carcinoma (HCC) with better anti-tumor effects than sorafenib, as shown by greater inhibition of the kinases of fibroblast growth factor receptor and vascular endothelial growth factor (VEGF) receptor. This report describes a patient with advanced HCC who experienced perforation of the small intestine 1 month after starting the treatment with lenvatinib. This patient likely had partial necrosis of a metastasis to the small intestine before starting lenvatinib treatment, with subsequent ischemic changes leading to perforation of the small intestine. Although metastasis of HCC to the small intestine is rare, patients with these metastases should be regarded as being at risk for perforation during lenvatinib treatment.
Identifiants
pubmed: 32110202
doi: 10.1159/000505774
pii: crg-0014-0063
pmc: PMC7036537
doi:
Types de publication
Case Reports
Langues
eng
Pagination
63-69Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest to disclose.
Références
J Clin Endocrinol Metab. 2016 Nov;101(11):4103-4109
pubmed: 27548104
Lancet. 2012 Mar 31;379(9822):1245-55
pubmed: 22353262
World J Gastroenterol. 2019 Feb 21;25(7):789-807
pubmed: 30809080
Invest New Drugs. 2018 Apr;36(2):350-353
pubmed: 29018997
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Crit Rev Oncol Hematol. 2014 Mar;89(3):394-403
pubmed: 24182420
Endocr Rev. 2004 Aug;25(4):581-611
pubmed: 15294883
Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H560-76
pubmed: 16172168
Int J Mol Med. 2016 Jul;38(1):3-15
pubmed: 27245147
Endocrine. 2017 Apr;56(1):121-128
pubmed: 28155175
Endoscopy. 1990 May;22(3):118-23
pubmed: 2162757
JAMA. 2008 Nov 19;300(19):2277-85
pubmed: 19017914
JAMA Oncol. 2017 Dec 1;3(12):1683-1691
pubmed: 28983565
J Thyroid Res. 2014;2014:638747
pubmed: 25295214
Clin Dev Immunol. 2012;2012:492920
pubmed: 23320019